JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be administered orally.
During a phase 2 dose-finding trial, investigators randomly assigned patients to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily or placebo for a period of 16 weeks.
A total of 255 patients were selected for randomization. The primary end point of the study was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score at week 16.
Results of the study demonstrated that at week 16, a higher percentage of patients in the JNJ-77242113 groups saw PASI 75 than those in placebo group, with researchers noting a significant dose-response relationship.
- 37% from the 25 mg once daily group
- 51% from the 25 mg twice daily group
- 58% from the 50 mg once daily group
- 65% from the 100 mg once daily group
- 79% from the 100 mg twice daily group
The most common adverse events reported during the study included coronavirus disease 2019 and nasopharyngitis.
